Financings in Brief: CompuCyte
This article was originally published in The Gray Sheet
Executive SummaryCompuCyte: Receives $2 mil. equity investment from San Diego-based healthcare alliance American Healthcare Systems, bringing total investments in Cambridge, Massachusetts-based CompuCyte to $8.6 mil. CompuCyte's first product, the Pathfinder system, "attaches to a lab technologists' microscope and displays on a computer monitor all the areas of a Pap smear slide that have been examined -- as well as areas that were missed," helping to avoid "potentially fatal mistakes that may result from incomplete and/or inadequate screening of Pap smears," the firm says. Currently undergoing tests, the device is expected to become available to hospitals and labs throughout the U.S. this fall...
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a CDC says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.